TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05144555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed orthodontic treatment with stainless steel brackets
Description: Stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed orthodontic treatment with ceramic brackets
Description: Ceramic brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment.
Study: NCT05638295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotorasib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Given PO
Study: NCT06648473

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Subjects will begin the MRI with T1-pre, T2w, and volumetric 3D FLAIR images being obtained. The subject will be brought out of the MRI magnet and moved into a seated position and will then have a standard Brain Tumor Imaging Protocol MRI scan.
Study: NCT06574828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091-matched Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIIB091-matched Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-matched Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin-matched Placebo
Description: Administered as specified in the treatment arm.
Study: NCT06125951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanamem
Description: Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient.
Study: NCT04890236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Given via infusion
Study: NCT05611775

Intervention type: DEVICE
Group type: OTHER
Intervention: Triaxial accelerometer
Description: Monitors placed on the waist, thigh, and bilateral ankles. Accelerometry will measure patients' physical activities in the free-living environment for 4 consecutive days. The patients will wear the monitor during waking hours and remove it during sleeping, showering, and swimming time.
Study: NCT05931367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05956964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction
Description: 5 hours of sleep for 3 days

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Adequate
Description: 9 hours of sleep for 3 days
Study: NCT06444867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 158968
Description: SC injection
Study: NCT05644262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2:C100
Description: The active study intervention, T2:C100, is an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in a digestible oil. T2:C100 is a full spectrum oral solution with five non-reactive ingredients: delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), a pharmaceutical grade medium chain triglyceride (MCT) oil, and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL study drug (T2:C100) twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL study drug twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks)).~Participants who enter the Open Label Extension will receive 1mL study drug (T2:C100) twice daily for Week 12 - Week 13 (approximately 1 week), and will then increase to 2mL study drug twice daily for the remainder of the Open Label Extension (Week 13 - Week 26 (approximately 23 weeks)).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo in a digestible oil. The placebo contains only three non-reactive ingredients: medium chain triglyceride (MCT) oil and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL placebo twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL placebo twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks)).
Study: NCT05736692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Sleep Intervention
Description: A \~50-minute semi-structured intervention based on the behavioral sleep medicine literature, particularly for adolescent insomnia, focused on key elements that can be addressed in one session. Treatment elements include engaging motivation, goal setting, barrier identification, problem-solving, pre-planning, self-monitoring, and setting rewards. The interventionist will be sensitized to barriers to sleep quality and quantity particularly relevant during adolescence, including job/work, homework, and social obligations, use of nicotine and caffeine, and social media and electronic devices. The interventionist will converse primarily with the adolescent, but parents will remain in the room as a support in problem-solving and executing therapeutic plans.
Study: NCT05372419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Administered SC
Study: NCT06298851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilization Group (NMG)
Description: Femoral nerve gliding: Mobilization of the femoral nerve will performed while the participant in the prone position and the hip hyperextended. Tension will applied by placing the knee in full flexion and the ankle in plantar flexion.~Sciatic nerve gliding: Participants will take turns while sitting with the trunk in thoracic flexion; perform knee extension/dorsiflexion with cervical extension and knee flexion/plantar flexion with cervical flexion. Tension will applied by flexing the hip and dorsiflexing the ankle to the point where stress will felt.~Peroneal nerve gliding: The participant will asked to maintain this position in a supine position by placing the ankle in inversion and plantar flexion. From a starting position consisting of ankle dorsiflexion, knee, and hip extension, the patient will return to the starting position by simultaneously performing ankle plantar flexion and inversion, full knee flexion, and 90 degrees of hip flexion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching Group (DSG)
Description: Exercises will include functional activities that provided dynamic stretching of the hamstrings, quadriceps, hip flexor, extensor, abductor and adductor muscles, and gastrosoleus muscle. All stretching exercises will be performed in two circuits in an area of 15 m2. 4 sets of 10 repetitions will be performed, each exercise cycle lasting 6 seconds, and a 1-minute rest period will be given between sets. This process will be repeated for both extremities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching Group (SSG)
Description: Static stretching exercises will be described to the participants as given below:~Standing quadriceps stretch: The participant will stand upright, fold one knee and bring the heel towards the buttock while holding the foot with one hand.~Modified hamstring stretching: The participant will be in a seated position with one leg straight and will place the other foot on the inside of the straight leg and reach forward.~Gastrocnemius stretching: The participant stands with feet 60-90 cm from the wall, leaning against the wall with both hands, keeping the back leg straight and the front leg slightly bent.~Adductor stretching: Participants will be in a sitting position with an erect spine, bending and releasing their knees with the soles of their feet touching.~Lumbar stretching: In a sitting position, participants keep one leg straight and place the other foot on the outside of the straight leg and rotate the body diagonally.
Study: NCT04819100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT06084481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion
Study: NCT06408337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implantation with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT).
Description: cleft palate repair surgery, all patients in the study will receive the standard treatment (uranostaphyllorrhaphy), with the only difference that patients assigned to the experimental study group will additionally have BIOCLEFT tissue obtained through tissue engineering grafted onto them. the lateral area of the palatine bone exposed when mobilizing the flaps. For the implant, the BIOCLEFT fabric will be placed in the area of exposed bone, sized to the size of the defect and sutured using uncoated, monofilament long-term absorbable synthetic suture.
Study: NCT05750563

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diosmin and micronized flavonoids
Description: the symptomatic treatment of haemorrhoids

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use as comparator
Study: NCT05317429

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A meal delivering 75 g of carbohydrate
Description: The nature of the test meal will depend upon the research question being addressed and it is anticipated that the test meals may include (but are not limited to) the following:~(i) Re-structured, enriched, and/or reformulated or non-conventionally processed food products (ii) Model food matrices with different structures or types of carbohydrate e.g. soups with different viscosity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A meal delivering 75 g of carbohydrate
Description: The nature of the test meal will depend upon the research question being addressed and it is anticipated that the test meals may include (but are not limited to) the following:~(i) Re-structured, enriched, and/or reformulated or non-conventionally processed food products (ii) Model food matrices with different structures or types of carbohydrate e.g. soups with different viscosity.
Study: NCT06084481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion
Study: NCT06039644

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Three-strain probiotic supplement includes Lactobacillus reuteri GMNL-89 (alive), Lactobacillus plantarum GMNL-141 (alive) and Lactobacillus paracasei GMNL-133 (alive).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.
Study: NCT06212986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Promotion of mental training through mobile application Perform-UP Tennis
Description: Perform-UP Tennis is a sport specific mental training app that integrates breathing, relaxation and na-ture-based guided imagery exercises and aims to promote emotional well-being and the enhancement of mental skills. The app techniques are integrated into a single gradual path that involves increasingly complex breathing and relaxation exercises with increasing duration.~The intervention consists of eight weekly modules over a period of 8 weeks with progressive exercises.
Study: NCT05603585

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Optimal protein supplementation to achieve 80% protein adequacy.
Description: Additional protein required and delivered by adding protein powder and given in bolus feeds
Study: NCT05482503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12-Lead ECG(I-lead)
Description: All participants will simultaneously record 12-lead ECGs(I-lead)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12-Lead ECG(I-lead)
Description: All participants will simultaneously record 12-lead ECGs(I-lead)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12-Lead ECG(I-lead)
Description: All participants will simultaneously record 12-lead ECGs(I-lead)
Study: NCT04743934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 MG
Description: Flibanserin 100mg tablets taken by mouth daily at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually identical placebo tablets taken by mouth daily at bedine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Androgen deprivation therapy
Description: Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.
Study: NCT05220514

Intervention type: DRUG
Intervention: (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)
Description: Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
Study: NCT05423522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoLithium® NP03
Description: One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
Study: NCT05490446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebapivat
Description: Tebapivat Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebapivat
Description: Tebapivat Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebapivat
Description: Tebapivat Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebapivat
Description: Tebapivat Tablet
Study: NCT05534321

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Radiotherapy
Description: Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) techniques may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care systemic therapy
Description: Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
Study: NCT06630494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin for injection (rhTPO)
Description: Single abdominal subcutaneous injection of the study drug will be given on D1. The administration and follow-up observation period will be 29 days (D1\~D29). Participants may be discharged at D7 at the judgment of the investigator. PK blood samples will be collected from D-1 to D14, tolerance and safety will be observed from D1 to D29, and blood samples for PD and anti-drug antibody (ADA) will be collected from screening to D29. After completion of relevant assessments on D29, participants will be considered as having completed this study.
Study: NCT06246084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy Education Program
Description: Brief, video-based intervention program to improve endocrine therapy adherence and experiences and to provide detailed education to participants. The intervention is distributed and assessed via the MyEmma platform, a HIPAA-compliant, online communications platform.
Study: NCT06502366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDA MDI HFO 160/180 μg
Description: Budesonide/albuterol pressurized inhalation suspension, HFO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDA MDI HFA 160/180 μg
Description: Budesonide/albuterol pressurized inhalation suspension, HFA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI HFA
Description: Placebo pressurized inhalation suspension, HFA
Study: NCT05220514

Intervention type: DRUG
Intervention: (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)
Description: Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.

Intervention type: DRUG
Intervention: 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)
Description: Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.

Intervention type: DRUG
Intervention: 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)
Description: Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
Study: NCT06202703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine
Description: vaccination with pneumococcal vaccine (PCV13)
Study: NCT04727736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: 18F-DCFPyL (single dose injection) - a radiolabeled prostate-specific membrane antigen (PSMA) ligand
Study: NCT04464967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex vivo expanded autologous natural killer cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex vivo expanded autologous natural killer cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex vivo expanded autologous natural killer cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex vivo expanded autologous natural killer cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex vivo expanded autologous natural killer cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex vivo expanded autologous natural killer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody